This week we’ll be releasing the results of our survey of over 600 Scientists currently using, or planning to adopt, CRISPR/Cas9 on their research.
Since the advent of molecular biology technology in the 1970s, there has been steady progress in the ability to alter, or edit, gene sequences at the genomic level. The recent development of CRISPR/Cas9 technology, however, has revolutionized the gene editing field, permitting rapid and specific gene sequence manipulations both in vitro and in vivo.
While this new technology builds on previous gene editing methods, such as TALENs and ZFN, it also critically depends on the successful application of other rapidly advancing, enabling technologies. Cell-based assay procedures and bioinformatics must pave the way before CRISPR/Cas9 core methodologies can be initiated.
Following CRISPR gene modification, techniques such as next-generation DNA sequencing and droplet digital PCR (ddPCR) must be applied to analyze and confirm results of gene modifications. These latter technologies also provide the basis to understand cellular gene sequences before specific CRISPR modifications can be proposed. Such analysis permits the application of CRISPR to a truly staggering number of tissue and cell types, starting with stable cell lines, and progressing all the way to stem cells, or even in real-time, patient-derived cancer cells.
In other words, the developing market for CRISPR/Cas9 products is going to impact companies selling the enabling technologies that make this revolutionary technique so powerful. Our report provides critical insights on how fast this market is growing, which suppliers are preferred and what customers need to propel their research forward.